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Abstract
Background: Recent studies have found that overexpression of the High-mobility group box-1 (HMGB1) protein, in
conjunction with its receptors for advanced glycation end products (RAGEs) and toll-like receptors (TLRs), is
associated with proliferation of various cancer types, including that of the breast and pancreatic.
Results: We have developed a rule-based model of crosstalk between the HMGB1 signaling pathway and other
key cancer signaling pathways. The model has been simulated using both ordinary differential equations (ODEs)
and discrete stochastic simulation. We have applied an automated verification technique, Statistical Model
Checking, to validate interesting temporal properties of our model.
Conclusions: Our simulations show that, if HMGB1 is overexpressed, then the oncoproteins CyclinD/E, which
regulate cell proliferation, are overexpressed, while tumor suppressor proteins that regulate cell apoptosis
(programmed cell death), such as p53, are repressed. Discrete, stochastic simulations show that p53 and MDM2
oscillations continue even after 10 hours, as observed by experiments. This property is not exhibited by the
deterministic ODE simulation, for the chosen parameters. Moreover, the models also predict that mutations of RAS,
ARF and P21 in the context of HMGB1 signaling can influence the cancer cell’s fate - apoptosis or survival -
through the crosstalk of different pathways.
Background
The cell cycle is strictly regulated and controlled by a
complex network of signaling pathways [1], comprised
of hundreds of proteins. If some important proteins are
mutated or there are defects in the signaling mechan-
isms, normal cell growth regulation will break down,
possibly leading to the occurrence of cancer in the
future. Moreover, a number of extracellular proteins can
bind to their receptors and activate signaling pathways
that promote the proliferation of cancer cells.
The high-mobility group box-1 (HMGB1) protein is a
DNA-binding nuclear protein, released actively in
response to cytokine stimulation, or passively during cell
death [2], and it is present in almost all eukaryotic cells
[3-6]. HMGB1 can activate a series of signaling compo-
nents, including mitogen-activated protein kinases
(MAPKs) and AKT, which play an important role in
tumor growth and inflammation, through binding to dif-
ferent surface receptors, such as RAGE and TLR2/4.
Several studies have shown that elevated expression of
HMGB1 occurs in many tumors [7-10] and accelerates
cell-cycle progression. Recent in vitro studies with pan-
creatic cancer cells [11] revealed that the targeted
knockout or inhibition of HMGB1 and RAGE could
increase apoptosis and suppress pancreatic cancer cell
growth. This phenomenon has been also observed with
lung cancer and other types of cancer cells [8,12].
The HMGB1 signal transduction can influence the
cell’s fate by two important processes - apoptosis and
cell proliferation - which are regulated respectively by
the proteins p53 and CyclinE, acting in two different
signaling pathways. The protein p53 is one of the most
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important tumor suppressor proteins: its activation can
lead to cell cycle arrest, DNA repair, or apoptosis.
Mutations of p53 occur at a frequency of 50% or higher
in many different cancer types [13]. CyclinE is a cell
cycle regulatory protein which regulates the G1-S phase
transition during cell proliferation. Cancer cells often
exhibit high expression levels of CyclinE and aberrant
CyclinE activity [14]. Many studies have found evidence
of crosstalk between the two signaling pathways invol-
ving p53 and CyclinE [15]. The crosstalk is regulated by
tumor suppressor proteins, including ARF, P21 and
FBXW7, which are also frequently mutated in many
cancers. In this paper, we ask the following questions:
How do these proteins and their mutations change the
cell’s fate - apoptosis or survival - when HMGB1 signal
transduction is activated? Which signaling pathways are
fundamental for describing HMGB1 signal transduction,
and what mechanisms are responsible to explain recent
results linking overexpression of HMGB1 with decrease
of apoptosis (and increased cancer cell survival)?
To the best of the authors’ knowledge, no computa-
tional model has been proposed to investigate the
importance of HMGB1 in tumor proliferation. In this
work, we construct a simple model of HMGB1 signal
transduction to investigate tumorigenesis on the basis of
known signaling pathway studies [16-21]. We also con-
structed a crosstalk network between these known path-
ways based on hypothetical mechanisms suggested by
recent experiments. The HMGB1 pathway is not well
understood at the mechanistic level, so our model can
provide some insights into the study of HMGB1’s roles
in tumor proliferation. A series of deterministic and sto-
chastic simulation experiments was conducted to inves-
tigate the properties of the HMGB1 pathway.
Finally, we analyze our pathway model against inter-
esting behavorial properties by means of Model Check-
ing techniques. Model Checking is an automated
verification technique for hardware and software sys-
tems [22]. Recently, there has been growing interest in
formal verification of stochastic systems, and, which has
recently seen a growing number of applications to biolo-
gical systems [23-25], by means of Model Checking
techniques. The Methods section introduces statistical
model checking, which we then apply to validate our
pathway model against experimental results from the
literature.
Methods
HMGB1 signaling pathway
Our HMGB1 signaling pathway model is illustrated in
Fig. 1. It includes 31 molecular species (6 tumor sup-
pressor proteins), 59 chemical reactions, and three dif-
ferent signaling pathways activated by HMGB1: the
RAS-ERK, Rb-E2F and p53-MDM2 pathways. Since the
interaction between HMGB1 and its receptors TLR and
RAGE is not clear at the mechanistic level, RAGE is
used to represent all the receptors in our model in
order to reduce the number of unknown parameters.
We now briefly discuss the three pathways and their
crosstalk. We denote activation (or promotion) by ®,
while inhibition (or repression) is denoted by ⊣.
The p53-MDM2 pathway is regulated by a negative
feedback loop [26]: PI3K ® PIP3 ® AKT ® MDM2 ⊣
p53 ® MDM2, and a positive feedback loop: p53 ®
PTEN ⊣ PIP3 ® AKT ® MDM2 ⊣ p53. The protein
PI3K is activated by the toll-like receptors (TLR2/4)
within several minutes after TLR2/4 activation by
HMGB1 [27]. In turn, PI3K phosphorylates the phos-
phatidylinositol 4,5-bisphosphate (PIP2) to phosphatidy-
linositol (3,4,5)-trisphosphate (PIP3), leading to
phosphorylation of AKT. The unphosphorylated onco-
protein MDM2, which is one of p53’s transcription tar-
gets [28], resides in the cytoplasm, and cannot enter the
nucleus until it is phosphorylated by activated AKT.
The phosphorylated MDM2 translocates into the
nucleus to bind with p53, inhibiting p53’s transcription
activity and initializing p53 polyubiquitination [29],
which targets it for degradation. Also, p53 can regulate
the transcription of PTEN [30], a tumor suppressor pro-
tein, which can hydrolyze PIP3 to PIP2, thereby inhibit-
ing the activation of AKT and MDM2.
The RAS-ERK pathway is the activation sequence:
RAS ® RAF ® MEK ® ERK ® CyclinD. Activation of
RAGE by HMGB1 leads to RAS activation, which in
turn activates its effector protein RAF. Activated RAF
will phosphorylate the MEK proteins (mitogen-activated
protein kinase kinases (MAPKK)), leading to the phos-
phorylation of ERK1/2 (also called MAPKs). Activated
ERK can phosphorylate some transcription factors
which activate the expression of the regulatory protein
CyclinD and Myc, enabling progression of the cell cycle
through the G1 phase. K-RAS, a member of the RAS
protein family, is found to be mutated in over 90% of
pancreatic cancers [31].
The Rb-E2F pathway is composed of the interactions:
CyclinD ⊣ Rb ⊣ E2F ® CyclinE ⊣ Rb. The Rb-E2F path-
way regulates the G1-S phase transition in the cell cycle
during cell proliferation. E2F is a transcription factor
that can activate the transcription of many proteins
involved in DNA replication and cell-cycle progression
[32]. In quiescent cells, E2F is bound by unphosphory-
lated Rb - a tumor suppressor protein - forming an Rb-
E2F complex which inhibits E2F’s transcription activity.
E2F will be activated and released when its inhibitor Rb
is phosphorylated by some oncoproteins (CyclinD and
Myc in Fig. 1), leading to the transcription of CyclinE
and Cyclin-dependent protein kinase 2 (CDK2) which
promote cell-cycle progression. CyclinE, in turn,
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continues to inhibit the activity of Rb, leading to a posi-
tive feedback loop [33-35]. Fig. 1 shows that the activity
of CyclinD-CDK4/6 (only CyclinD is shown in Fig. 1) is
inhibited by the tumor suppressor protein INK4A,
which is inactivated in up to 90% pancreatic cancers
[36].
The crosstalk between these pathways can influence
the cell’s fate since the three signaling pathways in
HMGB1 signal transduction are not independent. As
shown in Fig. 1, the oncoprotein RAS can also activate
the PI3K-AKT signaling pathway; the tumor suppressor
ARF protein induced by E2F can bind to MDM2 to pro-
mote its rapid degradation and stabilize p53. Further-
more, it has been experimentally observed [13] that the
p53-dependent tumor suppressor proteins P21 and
FBXW7 can inhibit the activity of cyclin dependent
kinases (In Fig. 1, we use P21 to represent both P21 and
FBXW7’s contribution). Mutations of RAS, ARF, P21
and FBXW7 have been found in many cancers
[31,36,37]. One of our aims is to investigate how these
mutations might influence the cell’s fate.
In the HMGB1 model, all substrates are expressed in
the number of molecules; proteins with the subscript
“a” or “p” correspond respectively to active or phos-
phorylated forms of the proteins. For example,
• RAGE (RAGEa) - inactive (active) form of
HMGB1’s receptor
Figure 1 Schematic view of HMGB1 signal transduction. Blue nodes represent tumor suppressor proteins; red nodes represent oncoproteins/
lipids; brown node represents protein complex formed by oncoprotein E2F and tumor suppressor protein RB. Solid lines with arrows denote
protein transcription, degradation or changes of molecular species; dashed lines with arrows denote activation processes.
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• MDM2 (MDM2p) - unphosphorylated (phosphory-
lated) MDM2.
We denote the mRNA transcript of MDM2 by mdm2.
We assume that the total number of active and inactive
forms of the RAGE, PI3K, PIP, AKT, RAS, RAF, MEK,
and ERK molecules is constant. For example, AKT +
AKTp = AKTtot, PIP2 + PIP3 = PIPtot. We sometimes
use CD to stand for the CyclinD-CDK4/6 complex, CE
for CyclinE, and RE for the Rb-E2F complex.
The p53-MDM2 and RAS-ERK pathways have been
studied individually using deterministic ODE methods
[16-19,32]. We instead formulated a reaction model cor-
responding to the reactions illustrated in Fig. 1 in the
form of rules specified in the BioNetGen language [38].
We used Hill functions to describe the rate laws govern-
ing protein synthesis, including PTEN, MDM2, CyclinD
(CD), Myc, E2F and CyclinE (CE). Our choice was moti-
vated by several studies [19,39-41], which showed that
transcription rates of these proteins are sigmoidal func-
tions of transcription factor (TF) concentrations with
positive cooperative Hill coefficients. We used mass
action rules for other types of chemical reactions. Both
ODEs and Gillespie’s stochastic simulation algorithm
(SSA) [42] are used to simulate the model with BioNet-
Gen [38]. Stochastic simulation is important because
when the number of molecules involved in the reactions
is small, stochasticity and discretization effects become
more prominent [43-45]. In the online Additional file 1,
we list 23 ordinary differential equations which describe
the deterministic HMGB1 model and all the input para-
meters. The BioNetGen code which implements SSA
and ODE models is available at [46].
Since our understanding of many chemical reactions
at the mechanistic level is not clear, a large number of
parameters involved in these reactions are difficult to
estimate based on existing data. We emphasize that in
our HMGB1 model the values for some undetermined
parameters were chosen in order to produce a qualita-
tive agreement with previous experiments.
Model Checking
Model Checking [22,47] is one of the leading techniques
for the automated verification and analysis of hardware
and software systems. Given a high-level behavior speci-
fication, a model checker verifies whether a system (or
model) satisfies it. A specification might be satisfied by
many different models. Thus, model checking is the
process of determining whether or not a given system
model satisfies (is a model of) a property describing the
desired behavior of the system. Mathematically, system
models take the form of state-transition diagrams, while
some version of temporal logic [48] is used to describe
the desired properties (specifications) of system execu-
tions. A typical property stated in temporal logic is G
(grant_req® F ack), meaning that it is always (G = glob-
ally) true that a grant request eventually (F = future)
triggers an acknowledgment. One important aspect of
Model Checking is that it can be performed algorithmi-
cally - user intervention is limited to providing a system
model and a property to check.
The Probabilistic Model Checking problem (PMC) is to
decide whether a stochastic model satisfies a temporal
logic property with a probability greater than or equal to
a certain threshold. To express temporal properties, we
use a logic in which the temporal operators are equipped
with bounds. For example, the property “CyclinD will
always stay below 10 in the next fifty time units” is writ-
ten as G50(CyclinD < 10). We now ask whether our sto-
chastic system M satisfies that formula with a probability
greater than or equal to a fixed threshold (say 0.9), and
we write M |= Pr≥ 0.9[G
50(CyclinD < 10)]. In the next sec-
tion, we formally define the temporal logic used in this
work, Bounded Linear Temporal Logic [23].
Bounded Linear Temporal Logic (BLTL)
Let SV be a finite set of real-valued variables, an atomic
proposition AP be a boolean predicate of the form e1 ~
e2, where e1 and e2 are arithmethic expressions over
variables in SV, and ~ is either ≥, ≤, <, >, or = . A BLTL
property is built over atomic propositions using boolean
connectives and bounded temporal operators. The syn-
tax of the logic is the following:
       :: | | | | .= ∨ ∧ ¬AP t1 2 1 2 1 1 2U
The bounded until operator 1 U
t 2 requires that,
within time t, 2 will be true and 1 will hold until
then. Bounded versions of the F and G operators can be
easily defined: Ft  = true Ut requires  to hold true
within time t;Gt  = ¬Ft ¬  requires  to hold true up
to time t.
The semantics of BLTL is defined with respect to
traces (or executions) of a system. In our case, a trace
will be the output of a simulation of a BioNetGen sto-
chastic model. Formally, a trace is a sequence of time-
stamped state transitions of the form s = (s0,t0), (s1,
t1),..., which means that the system moved to state si+1
after having sojourned for time ti in state si. The fact
that a trace s satisfies the BLTL property  is written as
s |= . We denote the trace suffix starting at step k by
s k. We have the following semantics of BLTL:
• s k ⊨ AP if and only if AP holds true in state sk;
• s k ⊨ 1 ∧ 2 if and only if s k ⊨ 1 and s k ⊨ 2;
• s k ⊨ 1 ∨ 2 if and only if s k ⊨ 1 or s k ⊨ 2;
• s k ⊨ ¬1 if and only if s k ⊨ 1 does not hold;
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• s k ⊨ 1 Ut2 if and only if there exists i Î N such
that, (a) ∑0 ≤ l <i tk+l ≤ t, (b) sk+i ⊨ 2 and (c) for
each 0 ≤ j <i, sk+j ⊨ 1.
The semantics of BLTL are defined over infinite traces,
but it can be shown that traces of an appropriate (finite)
length are sufficient to decide BLTL properties [49].
Statistical Model Checking
We briefly explain Statistical Model Checking [50,51], the
technique we use for verifying BioNetGen models simu-
lated by Gillespie’s algorithm. Statistical Model Checking
treats the Probabilistic Model Checking problem as a sta-
tistical inference problem, and solves it by randomized
sampling of the traces (simulations) from the model. In
particular, the PMC problem is naturally phrased as a
hypothesis testing problem, i.e., deciding between two
hypotheses - M ⊨ Pr≥θ[] versus M ⊨ Pr< θ[]. In other
words, to determine whether a stochastic system M satis-
fies  with a probability p ≥ θ, we test the hypothesis H0 :
p ≥ θ against H1 : p < θ. Sampled traces are model
checked individually to determine whether a given prop-
erty  holds, and the number of satisfying traces is used
by a hypothesis testing procedure to decide between H0
and H1. Note that Statistical Model Checking cannot guar-
antee a correct answer to the PMC problem. However, the
probability of giving a wrong answer can be made arbitra-
rily small.
We have introduced a Bayesian sequential hypothesis
testing approach and applied it to the verification of rule-
based models of signaling pathways and other stochastic
systems [23,49]. Sequential sampling means that the
number of sampled traces is not fixed a priori, but is
instead determined at “run-time”, depending on the evi-
dence gathered by the samples seen so far. This often
leads to a significantly smaller number of sampled traces.
Suppose that the stochastic system M satisfies the
BLTL formula  with some (unknown) probability p.
The key idea behind statistical model checking [50] is
that the behavior of M (with respect to property ) can
be modeled by a Bernoulli random variable with success
parameter p. Such a random variable can be repeatedly
evaluated via system simulation in the following way.
Let s be a trace of M, then the Bernoulli random vari-
able X with (conditional) probability mass function:
f x p p p xx x( | ) ( ) { , }= − ∈−1 0 11 (1)
denotes the outcome of s ⊨  (i.e., model checking 
on s). In other words, we have that:
X
p
=
⎧⎨⎩
=
− = ¬
1
0 1
with probability
with probability
p ( | ),
( | ).
 
  (2)
Therefore, by running a system simulation (i.e., a Bio-
NetGen stochastic simulation) and by checking  on the
resulting trace we can obtain a sample from random
variable X. When a sample of X evaluates to 1 we call it
a success, otherwise, a failure.
Recall that in hypothesis testing we decide between a
null hypothesis H0 and an alternative hypothesis H1:
H p H p0 : : .  1  < (3)
The Bayesian approach assumes that p is given by a
random variable whose distribution is called the prior
distribution. The prior is usually based on our previous
experiences and knowledge about the system.
Since p is a probability, we need prior distributions
defined over [0,1]. In particular, Beta priors are mathe-
matically convenient to use. They are defined by the fol-
lowing probability density:
∀ ∈ = −− −u g u
B
u u[ , ] ( , , )
( , )
( )0 1
1
11 1   
  (4)
where the Beta function B(a, b) is defined as:
B t t dt( , ) ( ) .   = −− −∫ 101 11 (5)
For later use, the Beta distribution function F(a;b)(u) of
parameters a, b is defined as for all u Î [0, 1] as:
F u g t dt
u
( , )( ) ( , , )   = ∫0 (6)
= −
− −∫1 110 1B t t dtu( , ) ( ) .    (7)
Let d = (x1,..., xn) denote n samples of the Bernoulli
random variable X defined by (2). Let H0 and H1 be the
hypotheses in (3), and suppose that the prior probabil-
ities P (H0) and P (H1) are strictly positive and satisfy P
(H0) + P (H1) = 1. By Bayes’s theorem, the posterior
probabilities of H0 and H1, with respect to data d, are:
P H d
P d Hi P Hi
P d
ii( | )
( | ) ( )
( )
( , )= = 0 1
for every d with P (d) > 0. In our case, P (d) is always
non-zero (there are no impossible finite sequences of
data). The hypothesis test method is based on the Bayes
Factor, that is, the likelihood ratio of the sampled data
with respect to the two hypotheses. The Bayes Factor ℬ
of sample d and hypotheses H0 and H1 is
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 = P d H
P d H
( | )
( | )
0
1
and by Bayes’ theorem, we have that:
 = ⋅P H d
P H d
P H
P H
( | )
( | )
( )
( )
.0
1
1
0
(8)
Therefore, B can be interpreted as a measure of evi-
dence (given by the data d) in favor of H0. Now, fix a
threshold T > 1. The algorithm iteratively draws inde-
pendent and identically distributed (iid) sample traces in
the form of BioNetGen stochastic simulations, and
checks whether they satisfy  (Note that BioNetGen
ensures by construction that each simulation, or trace, is
actually iid.) After each trace, the algorithm computes
the Bayes Factor B to check if it has obtained conclusive
evidence. The algorithm accepts H0 if B >T, and rejects
H0 (accepting H1) if  < 1T . Otherwise 1T T≤ ≤( ) , it
continues drawing iid samples. The statistical Model
Checking algorithm is shown in Figure 2.
The following Proposition shows that, in our special
case of Bernoulli samples, the computation of the Bayes
Factor is straightforward.
Proposition 1. [49]The Bayes Factor of H0 : p ≥ θ vs.
H1 : p <θ with Bernoulli samples (x1,..., xn) and Beta
prior of parameters a, b is:
n
P H
P H F x n x
=
+ − +
−
⎛
⎝
⎜⎜
⎞
⎠
⎟⎟
( )
( )
•
( , )( )
1
0
1
1  
where x xii
n
=
=
∑ 1 is the number of successes in (x1,...,
xn) and F(s,t)(·) is the Beta distribution function of para-
meters s, t.
The Beta distribution function can be efficiently com-
puted by standard software packages. Thus, no numeri-
cal integration is required for the evaluation of the
Bayes Factor.
Finally, we must show that the error probability of our
decision procedure, i.e., the probability that we reject
(accept) the null hypothesis although it is true (false),
can be bounded.
Theorem. [49] The error probability for the sequential
Bayesian hypothesis testing algorithm is bounded above
by 1T where T is the Bayes Factor threshold given as
input.
Results and discussion
We first conducted a series of deterministic and sto-
chastic simulation experiments to study the properties
of our HMGB1 signaling pathway model. Then, we
applied the statistical model checking technique to vali-
date some important temporal properties of our
HMGB1 model.
Simulation results
We carried out a baseline simulation for four important
proteins - p53, MDM2p, CyclinD/E - using ODE and
stochastic simulation. We set the initial value for the
number of HMGB1 molecules to be 103; Table 1 lists all
proteins with nonzero initial values; the unlisted pro-
teins are set to 0 initially.
Figure 2 Statistical Model Checking Algorithm. The algorithm for Statistical Model Checking is based on Bayesian Hypothesis Testing.
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The baseline stochastic simulations in Fig. 3A demon-
strate that the expression levels of p53 and MDM2p
oscillate even after 10 hours, when the cell enters the S
phase (recall that cells usually remain in phase G1 for
about 10 hours before moving to the S phase). However,
oscillations are strongly damped in the ODE simulations
(Fig. 3C) when the cell proceeds to the S phase, approxi-
mately after 10 hours. The stochastic simulation model
is thus more consistent with the experimental results of
Geva-Zatorsky et al. [52]. In that experiment the authors
measured the dynamics of p53 and MDM2p in human
breast cancer cells damaged by g radiation. It was
observed that the oscillations of p53 and MDM2p
expression levels can last more than 72 hours after
irradiation.
Fig. 3B and 3D show that the CyclinE protein, which
regulates the G1-S phase transition in the cell cycle,
reaches its maximum at about 10 hours, after which the
cell proceeds with DNA replication (S phase). How does
the expression level of HMGB1 and other proteins influ-
ence the cell’s fate? We varied the levels of HMGB1 and
AKT to determine how they affect cell behavior. A
number of studies have found that HMGB1 is overex-
pressed in many cancers, and the overexpression of
HMGB1 and its receptors can promote cancer cell
proliferation and decrease apoptosis [8,9]. In Fig. 4A-B,
we increase the initial values of HMGB1 from 1 to 106
and measure p53’s maximum expression level in phase
G1. We then measure the oncoproteins E2F and
CyclinD/E’s expression levels at 10 hours, which corre-
sponds to the G1-S phase transition point. For the sto-
chastic simulation, the experiment is repeated 10 times
per value to compute the mean and standard errors. Fig.
4(A, D) demonstrates that the increase of HMGB1’s
initial value will lead to a decrease of p53’s expression
level, but when the number of HMGB1 molecules is
over 105, p53 will not continue to decrease. This is
because HMGB1 can also activate and increase the
expression level of its downstream protein E2F (Fig. 4
(A, D)), whose overexpression will activate the transcrip-
tion of the tumor suppressor protein ARF, which can
inhibit MDM2’s activity to stabilize p53’s level. However,
ARF is found to be mutated in up to 80% of pancreatic
cancers [36,53]. This means that ARF cannot inhibit the
activity of the oncoprotein MDM2, thereby leading to
lower levels of the tumor suppressor p53.
Fig. 4(B, E) shows that the cell cycle regulatory pro-
teins CyclinD/E will increase with the elevated expres-
sion of HMGB1, a behavior which could be verified by
future experiments. Fig. 4(A-B, D-E) explains the
Table 1 Initial values for the model
RAGE PI3K PIP2 AKT MDM2 MDM2p P53 RAS RAF MEK ERK RE
103 105 105 105 104 2 × 104 2 × 104 104 104 104 104 105
Non-zero initial values of the proteins are listed in the table; other unlisted proteins are initially set to 0.
Figure 3 HMGB1 baseline simulation. Number of p53, MDM2p (A, C), CyclinD/E (B, D) molecules versus time for baseline simulations with SSA
(A-B) and ODE (C-D) models.
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experimental discovery that the overexpression of
HMGB1 decreases apoptosis and promotes DNA repli-
cation and proliferation in cancer cells.
The oncoprotein AKT is overexpressed in many can-
cers [54]. In Fig. 4(C, F), we first increase the number of
unphosphorylated AKT molecules and fix the other pro-
teins’ concentration, then measure p53 and MDM2p ’s
expression levels at 10 hours in phase G1 after HMGB1
activates its receptor RAGE. Fig. 4(C, F) shows that with
the increase of AKT’s expression level, p53 is repressed
due to the ubiquitination initiated by the overexpressed
MDM2p, which is promoted by the activated and over-
expressed AKT protein. The results in Fig. 4(C, F) sug-
gest a way to inhibit tumor cell proliferation and induce
tumor cell apoptosis through the inhibition of protein
phosporylation events downstream from AKT kinases in
the PI3K/AKT pathway, using an AKT kinase inhibitor
(such as the drug GSK-690693 [55]).
K-RAS is a member of the RAS protein family. K-RAS
mutation and ARF loss occur in more than 80% of pan-
creatic cancers [36,53]. The P21 and FBXW7 proteins
are also frequently mutated in many cancers [37]. ARF
and P21 play an important role in the crosstalk between
the p53 and Rb pathways. ARF is able to reroute cells
with oncogenic damage to p53-dependent fates through
binding to MDM2 and targeting its degradation. The
p53-dependent tumor suppressor proteins P21 and
FBXW7 can inhibit CyclinD/E’s activity to prevent the
proliferation of cancer cells.
Fig. 5 shows how mutations of ARF, P21 and FBXW7,
and K-RAS influence tumor suppressor and cell cycle
regulatory protein levels at 10 hours in the HMGB1 sig-
naling pathway. We use the MDM2 degradation rate
driven by ARF, dARF ( ′d7 in the ODE model), to
describe ARF mutations. Also, we use the Cyclin degra-
dation rate driven by P21 (dP21 for stochastic simulation,
and ′b6 for ODE simulation) to describe P21 and
FBXW7 mutations. Large dARF and dP21 values corre-
spond to small mutations of ARF and P21 respectively,
while small dARF and dP21 values correspond to large
ARF and P21 mutations in the cell.
Figure 4 HMGB1 and AKT sensitivity study. Overexpression of HMGB1 (A-B, D-E) leads to the increase of oncoprotein E2F and DNA
replication proteins CyclinD/E, and to the decrease of p53. Overexpression of AKT (C, F) activated by HMGB1 increases the expression level of
MDM2p and represses p53, using ODE (A-C) and SSA (D-F) simulations.
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Fig. 5(A, D) shows that wild-type ARF (large dARF )
can decrease the number of MDM2p molecules and
increase p53’s expression level to initiate apoptosis even
if the cell proceeds to the S phase. Moreover, mutated
ARF (smaller dARF ) can not stabilize p53 expression
and prevent the proliferation of cancer cells if HMGB1
is overexpressed. This could explain the phenomenon
that ARF loss exists in over 80% of pancreatic cancers
[36]. Fig. 5(B, E) demonstrates that CyclinD/E proteins
will increase if P21 is mutated (smaller dP21), thereby
accelerating cell cycle progression.
K-RAS is mutated in most cancers, especially in pan-
creatic cancer [31]. The activation of RAS is initiated by
HMGB1 and its receptors, and the wild-type RAS can
be deactivated by some kinases. Studies have found that
the mutated K-RAS can not be deactivated [56], even if
HMGB1 is knocked out, so it will continuously activate
the downstream signaling pathways which promote cell
proliferation. Fig. 5(C, F) shows that with the increase of
RAS deactivation rate dRAS (b1 in the ODE model), the
synthesis of CyclinD/E will be inhibited, but a small
deactivation rate of RAS will lead to overexpression of
CyclinD/E. The results visualized in Fig. 5 suggest some
ways to inhibit cancer cell proliferation through inhibi-
tion or deactivation of the signaling pathways involving
RAS, Cyclin, and Cyclin-dependent kinases (CDK).
Recently, CDK and RAS inhibitor drugs [57-59] have
been developed to inhibit tumor growth.
Verification of the HMGB1 model
We use Statistical Model Checking (SMC) to verify
some fundamental properties that our model should
satisfy. We test whether the model satisfies a given
BLTL property with probability p ≥ 0.9. We set the
threshold T = 1000 for the verification, so the probabil-
ity of a wrong answer is smaller than 10-3.
Property 1: p53 is normally expressed at low levels in
human cells. We verified the following property
Figure 5 Mutations of ARF, P21 and RAS affect the cell’s fate. Mutations of the tumor suppressor proteins ARF and P21, and of the
oncoprotein RAS affect the cell’s fate, using ODE (A-C) and stochastic (D-F) simulations. The mutations of ARF (A, D) and P21 (B, E), and RAS (C,
F), which correspond to small dARF and dP21, and large dRAS values, upregulate the expression level of the oncoproteins MDM2 and CyclinD/E,
and downregulate p53’s expression level.
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which informally means that the number of p53 mole-
cules will be less than a threshold value within t min-
utes, and it will always stay below this value during the
next 900 minutes. We verified this property with various
values of t and the results are shown in Table 2.
Property 2: p53’s expression level increases quickly in
response to various stresses, including the activation of
HMGB1. We verified the property
Pr P0 9 100 453 5 3 10. [ ( . )],F > ×
that is, within 100 minutes p53’s level will eventually
be larger than 5.3 × 104. SMC accepts this property as
true, after sampling 38 traces (of which 37 satisfying
traces).
Property 3: PI3K will be activated within a few min-
utes after HMGB1 binds to RAGE. We verified the fol-
lowing property
Pr PI K PI Ka tot0 9 20 3 3 0 5. [ ( / . )],F >
which means that half of PI3K will be activated within
20 minutes. We verified this property with various
values of HMGB1, and the results are shown in Table 3.
If HMGB1 was overexpressed (105), this property was
accepted as true (22 satisfying traces). But if the expres-
sion level of HMGB1 was very low, the property was
rejected.
Property 4: The overexpression of HMGB1 will pro-
mote the oncoprotein CyclinE’s expression before the
G1-S phase transition point, thereby facilitating the G1-
S phase transition. We verified the property
Pr CyclinE0 9 600 900. [ ( )],F >
that is, the number of CyclinE molecules will even-
tually exceed 900 within 600 minutes (10 hours). We
verified this property with various values of HMGB1
and the results are shown in Table 4.
Property 5: Mutation in K-RAS leads to continuous
activation of downstream pathways and overexpression
of CyclinD in the G1 phase during HMGB1-activated
signaling transduction. We verified the property:
Pr CyclinD0 9 600 900. [ ( )],F >
with different RAS deactivation rates (dRAS). The
results are presented in Table 4. Properties 4 and 5
show that the overexpression of HMGB1 and mutation
of RAS (small dRAS value) will accelerate the expression
of cell regulatory protein CyclinD/E to promote cell pro-
liferation. However, inhibition of HMGB1 and an
increase of RAS deactivation rate will prevent tumor
growth.
Property 6: Within 300 minutes, CyclinE’s expression
level becomes very low until 50% of RAS has been acti-
vated by HMGB1. We verified the property:
Pr CyclinE RAS RASa tot0 9 30010 0 5. [ ( ) ( / . )].< >U
SMC accepted this property as true (22 satisfying
traces).
Property 7: HMGB1 could influence the tumor sup-
pressor protein p53’s expression level, especially the first
peak of p53’s concentration in the G1 phase. We veri-
fied the following property:
Pr
p
a
p
  0 9 100 1005310000
53
10000
0 4. [ ( ( ))]. ,F F∧
which informally means that the number of p53 pro-
tein molecules in the nucleus will eventually be greater
than a threshold value a × 104 within 100 minutes, after
which it reduces to a low level within the next 100 min-
utes. We verified this property with various values of a
and HMGB1, and the results are shown in Table 5.
Conclusions
We have presented a reaction network model of the sig-
naling transduction initiated by HMGB1. The model
incorporates the contributions from the most important
known signaling components of the HMGB1 signal
transduction network. The model is expressed in the
form of BioNetGen rules, and simulated using ODEs
and Gillespie’s algorithm under a range of conditions.
We used Statistical Model Checking to automatically
Table 2 Verification of property 1
Property 1: Pr≥ 0.9[F
t(G900(P53 < 3.3 × 104))]
t(min) # of Samples # of Successes Result Time (s)
400 53 49 True 597.59
500 23 22 True 271.76
600 22 22 True 263.79
Property 1 specifies that the number of p53 molecules will be less than a
threshold value within t minutes, and it will always stay below this value
during the next 900 minutes. The initial value of HMGB1 is 103.
Table 3 Verification of property 3
Property 3: Pr ≥ 0.9[F
20(PI3Ka/PI3Ktot >0.5)]
HMGB1 # of Samples # of Successes Result Time (s)
103 9 0 False 6.49
9 × 103 380 315 False 285.16
105 22 22 True 16.39
Property 3 specifies that half of the PI3K molecules will be activated within 20
minutes when HMGB1 is overexpressed.
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validate our model with respect to known experimental
results.
Our simulations demonstrate a dose-dependent p53
and CyclinE response curve to increasing HMGB1 sti-
mulus. This hypothesis could be tested by future experi-
ments. In particular, overexpression of HMGB1
promotes the cell cycle regulatory proteins E2F and
CyclinD/E and inhibits the pro-apoptotic protein p53,
leading to increased cancer cell survival and decreased
apoptosis. This is consistent with experimental observa-
tions in recent studies of cancer cells [11]. We also
investigated the roles of different components in the
pathway and predicted their activity in response to var-
ious conditions. We investigated how mutations of the
RAS, ARF and P21 proteins influence the fate of the
cancer cell. In particular, parameter variation showed
that the mutated RAS increases the expression level of
CyclinE, leading to cancer cell proliferation. Mutation or
loss of the ARF protein leads to high MDM2 activity
and loss of p53 expression in the face of HMGB1 over-
expression, resulting in decreased apoptosis. Our model
shows that the inhibition (or deactivation) of RAS,
Cyclin, and Cyclin-dependent kinases (CDK) might inhi-
bit tumor growth.
Since our proposed model is based on just three sig-
naling pathways, we are far from capturing the entire
HMGB1 network dynamics. Studies have found that
HMGB1 can not only activate the PI3K-AKT and RAS-
ERK pathways, but can also activate the NFB signaling
pathway [27], which regulates many pro-apoptotic and
anti-apoptotic proteins’ transcription [60]. Since
HMGB1 could be released passively during necrosis,
there might exist crosstalk between the tumor necrosis
factor (TNF) pathway and the HMGB1 pathway. Besides
the incorporation of new pathways, recent work has
demonstrated that HMGB1 can bind to p53 directly to
influence p53-mediated transcriptional activity [61]. A
larger network for HMGB1 signal transduction will be
explored in our future work.
It has been recently observed that pancreatic tumor
cells increase autophagy [11] and release HMGB1 [10]
in response to chemotherapy, radiation, and hypoxia,
which may promote tumor cell survival. It has been
hypothesized that direct inhibition of autophagy may be
another way to inhibit tumor growth and enhance the
efficacy of cancer therapies [11]. The incorporation of
autophagic proteins into the HMGB1 signaling pathway
is worth considering in future work.
Although our current model can only qualitatively
compare with the experimental behavior, it still provides
valuable information about the behavior of HMGB1 sig-
nal transduction in response to different stimuli. Future
experiments will enable the development of more realis-
tic models. We anticipate that the application of model
checking techniques, such as those explored in this
work, will facilitate the development of targeted and
effective anti-cancer therapies.
Additional material
Additional file 1: Ordinary differential equations and model
parameters. The PDF file contains all the ordinary differential equations
that describe the HMGB1 signal transduction model, the input
parameters and their descriptions.
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